ArticleBMC systems biology2016
Drug combinatorics and side effect estimation on the signed human drug-target network.
Article in BMC systems biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Combination Drug Therapy for the Management of Chronic Neuropathic Pain.Biomolecules · 2023Review
- Multi-omics protein-coding units as massively parallel Bayesian networks: Empirical validation of causality structure.iScience · 2022Article
- Gain and loss of function mutations in biological chemical reaction networks: a mathematical model with application to colorectal cancer cells.Journal of mathematical biology · 2021Article
- Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients.Nucleic acids research · 2021Article
- Machine learning in the prediction of cancer therapy.Computational and structural biotechnology journal · 2021Review
- Drug Side-Effect Prediction Via Random Walk on the Signed Heterogeneous Drug Network.Molecules (Basel, Switzerland) · 2019Article
- Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.NPJ systems biology and applications · 2019Article
- Drug repositioning using drug-disease vectors based on an integrated network.BMC bioinformatics · 2018Article
- Global view of a drug-sensitivity gene network.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mode of action of a drug on its targets can often be classified as being positive (activator, potentiator, agonist, etc.) or negative (inhibitor, blocker, antagonist, etc.). The signed edges of a drug-target network can be used to investigate the combined mechanisms of action of multiple drugs on the ensemble of common targets.
resultsIn this paper it is shown that for the signed human drug-target network the majority of drug pairs tend to have synergistic effects on the common targets, i.e., drug pairs tend to have modes of action with the same sign on most of the shared targets, especially for the principal pharmacological targets of a drug. Methods are proposed to compute this synergism, as well as to estimate the influence of the drugs on the side effect of another drug.
conclusionsEnriching a drug-target network with information of functional nature like the sign of the interactions allows to explore in a systematic way a series of network properties of key importance in the context of computational drug combinatorics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.